

**Date: February 25, 2026**

**To  
BSE Limited  
25th Floor, PJ Towers  
Dalal Street,  
Mumbai – 400001  
Scrip Code: 524654**

**To  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400051  
Symbol: NATCAPSUQ**

**Sub: Newspaper Advertisement of the Postal Ballot Notice**

**Dear Sir/Madam,**

Please find enclosed herewith copies of the newspaper advertisement with respect to the Postal Ballot Notice & E-Voting information published in the following newspapers:

1. Business Line Daily; English Language.
2. Sanjevani Daily; Kannada Language.

We request you to kindly take the above information on your record.

**Thanking You.  
Yours Faithfully,**

**For Natural Capsules Limited**

**Pranjal Deshmukh  
Company Secretary & Compliance Officer**



## QUICKLY.

**Eris Lifesciences partners  
Natco for semaglutide**

**Mumbai:** Eris Lifesciences has announced a partnership with Natco Pharma for the commercialisation of semaglutide in India. Semaglutide is the active ingredient in Novo Nordisk's weightloss and diabetes drug Wegovy/Ozempic, and a patent on this ingredient is to expire this March in certain markets. **OUR BUREAU**

**Alembic gets nod to sell  
generic antifungal drug**

**New Delhi:** Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market generic antifungal medication. The company has received final approval from the United States Food and Drug Administration (USFDA) for Efnacazole Topical Solution (10 per cent). **PTI**

**Wishlink raises \$17.5 m  
in Series B funding**

**Bengaluru:** Wishlink, creator commerce platform, has raised \$17.5 million in its Series B funding round, led by Vertex Ventures Southeast Asia & India. The round also saw participation from existing investors Fundamentum and Elevation Capital. Wishlink plans to expand its creator and brand network, invest further in technology that improves shopping experiences for consumers, while enabling deeper collaboration between creators and brands. **OUR BUREAU**

# India has preferential access to two-thirds of global trade: Goyal

**IN ADVANCED STAGE.** I was involved in three FTA negotiations in a span of six hours, says Minister

**Our Bureau**  
Chennai

Even as the world grapples with uncertainty, India is focused on building "bridges of trade, bridges of trust and bridges of transformation" through a network of high-quality free trade agreements (FTAs), Union Commerce and Industry Minister Piyush Goyal said on Tuesday.

Addressing the valedictory session of the Confederation of Indian Industry's 5th National Exports Competitive Summit 2026 virtually, the Minister said India today enjoys preferential trade access to nearly two-thirds of global trade and is actively negotiating multiple FTAs simultaneously. "In a

span of six hours this evening, I have been engaged with three free trade agreement negotiations," he said.

India on Tuesday signed a joint statement to launch FTA negotiations with the six-nation Gulf Cooperation Council, while talks with Israel to finalise a bilateral FTA are at an advanced stage. New-age FTA discussions are also underway with Chile, focused on securing access to critical minerals.

**FTA NEGOTIATIONS**

Goyal said that with the Canadian Prime Minister expected in India shortly, both countries were hopeful of finalising terms of reference and launching FTA negotiations later this week.

The Minister said Prime Minister Narendra Modi has



**HIGH ON DEALS.** All nine FTAs concluded under the current government have been with developed economies that complement India's growth journey, Goyal said

built a strategic FTA network as part of India's de-risking strategy through diversified trade partnerships. "Merchandise trade with Australia and the UAE has doubled since the signing of FTAs with these countries," he said. All nine FTAs con-

cluded under the current government have been with developed economies that complement India's growth journey, he added.

Goyal urged industry leaders to take FTAs to the grassroots by creating awareness among MSMEs about tariff

benefits, services access and investment opportunities. He called for physical outreach, training programmes and mentorship models, suggesting that companies adopt districts or clusters to build local export ecosystems.

"When an MSME understands how a tariff cut can open new markets, it will make him a new exporter," he said.

India's export growth story, he said, is ultimately about confidence, resilience and aspiration.

"Every Indian — from the weaver in Kanchipuram to the entrepreneur in Chennai — is now a potential global exporter. Our task is to ensure the pathway is clear, support is accessible and opportunity is real," he added.

# Tiruppur targets \$10 billion exports to Europe

**Our Bureau**  
Chennai

India's knitwear hub Tiruppur is positioning itself for its next growth leap as free trade agreements (FTAs) with the UK and the European Union near fruition, industry leaders said at a summit in Chennai on Tuesday.

"We have set an ambitious target of \$10 billion in apparel exports by 2030," said N Thirukkumaran, Chairman, Esstee Exports India Ltd, Tiruppur, and Secretary Tiruppur Exporters Association.

India's total apparel exports currently stand at about \$16 billion, with Tiruppur alone contributing



**BIG CONTRIBUTION** India's total apparel exports currently stand at about \$16 billion, with Tiruppur alone contributing nearly \$5.2 billion

nearly \$5.2 billion — roughly a third of the country's shipments, he said at the CII's 5th National Exports Competitive Summit 2026.

With the Prime Minister setting a national target of \$40 billion in apparel exports as part of the broader \$100 billion textiles goal by 2030,

Tiruppur is expected to play a pivotal role, said Thirukkumaran.

**GAME CHANGER**

Exporters believe Europe will be a "game changer". While India has already signed trade agreements with the UAE and other GCC

countries, duty-free access to the UK and the EU could significantly improve Tiruppur's competitiveness against rival sourcing hubs.

Industry representatives noted that FTAs with a few European countries often open doors across the wider European market, multiplying export opportunities.

A key differentiator for Tiruppur, he said, is its cluster-level sustainability framework. Unlike other global apparel hubs where compliance is limited to individual firms, Tiruppur operates common effluent treatment plants and shared ESG infrastructure, making it one of the few clusters globally aligned with emerging environmental and social disclosure norms. With sustainabil-

ity set to become a baseline requirement for doing business, this advantage is expected to gain prominence, he said. Tiruppur cluster is also reorienting its growth strategy towards man-made fibre garments, athleisure and value-added products, reflecting global consumption trends.

Industry leaders acknowledged challenges in synthetic fibre supply chains but expressed confidence that new investments in fibres such as lycocell in Tamil Nadu would strengthen competitiveness, he said. Sunil Jhunjhunwala, Co-Founder, Techno Sportswear Pvt Ltd, said free and fair availability of raw materials and mobility of labour work force will be critical for the industry.

# Making complex, innovative products the next frontier: Pharma chiefs

**PT Jyothi Datta**  
Mumbai

The Indian pharmaceutical industry has achieved scale in making generic medicines, but the next frontier is in making complex and innovative products and adopt new capabilities including AI as they face geopolitical headwinds, among other challenges, said the top-management of leading pharmaceutical companies.

**AFFORDABILITY**

Making products that are affordable will be at the core, given that Indian drugmakers are able to make affordable versions of existing and newer products' censing or collaborations, he said, speaking at a panel discussion on the final day of the Quality Summit organised by the IPA — a platform largely for domestic drugmakers.

Sun Pharmaceuticals Executive Chairman Dilip Shanghi called for a recalibration of the pharma industry's generic thinking, in terms of investment decisions, for example.

Pointing out that he did not see "innovation at scale" yet in the industry, Shanghi

**'Producing products that are affordable will be at the core, given that Indian drugmakers are able to make affordable versions of existing and newer products'**

put it down to the lack of "familiarity" with the decision-making process, for example, in this landscape. The mindset needs to change from bringing out products "cheaper and better" to "faster and better", he said. And as more companies start to succeed in this journey, it would build the confidence of others in the industry, he added. Lupin Managing Director Nilesh Gupta also pointed out the need for more success stories. Citing Glenmark's success with out-licensing a prospective drug molecule, he said, "we need 10 more of this."

Madan Mohan Reddy, Whole Time Director with Aurobindo Pharma, said the present research spends of companies was not enough to innovate. The next decade will involve much change, he said, and the way ahead would be through more partnerships and collaborations, he said, with a strong accent on quality.

# Govt plans cervical cancer vaccination campaign for teenage girls

**PT Jyothi Datta**  
Mumbai

India is set to undertake a country-wide Human Papillomavirus (HPV) vaccination initiative for adolescent girls as part of a special public health campaign against cervical cancer — one of the most common yet preventable cancers affecting women, a source familiar with the development said.

The high-profile free rollout is just days away, a government source told *businessline*, on the national programme to vaccinate adolescents in the country.

India's public health infrastructure broke new ground with its vaccination programme during Covid-19, a first in adults.

This later extended to the youth as well. The country has, however, been running immunisation campaigns for infants for several decades.

The proposed HPV campaign covers adolescent girls (14-year-olds only), who will be vaccinated with the single dose Gardasil 4, a quadrivalent HPV vaccine that protects against HPV strains 16 and 18, which cause cervical cancer, besides 6 and 11. The programme is in line with the World Health Organization recommendation that identifies HPV vaccination as key to the Global Strategy to Eliminate Cervical Cancer. (Gardasil is the HPV vaccine from Merck Sharp & Dohme.)

About one crore vaccines have been supplied through India's partnership with Gavi, the Vaccine Alliance, and supplied to the States, the official said.

The total commitment is for 2.6 crore vaccines. There are about 1.15 crore girls in the 14-year bracket, the source added.

The vaccine is WHO-approved and single dose



(helping better adherence, compared to multiple dose vaccines), the source said, indicating its choice for the national programme.

Earlier reports suggested Serum Institute of India was to be part of this programme. Cervical cancer remains the second most common cancer among women in India, with nearly 80,000 new cases

# Bayer's prostate drug Nubeqa cleared for expanded use in non-chemo patients

**Our Bureau**  
Mumbai

Multinational company Bayer said its prostate cancer medicine Nubeqa has received approval in India for an expanded indication, offering clinicians access to a non-chemotherapy treatment option for patients who may not be able to tolerate chemotherapy.

"The expanded approval in India allows for Nubeqa to be used in combination with androgen-deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC)," a note from the company explained.

**LATEST INDICATION**

Bayer said the latest indication for mHSPC is approved in Korea, Thailand, Taiwan, Australia, US, the EU and now India.

Nubeqa was launched in

India in June 2022, with its first approved indication for non-metastatic castration-resistant prostate cancer (nmCRPC), followed in 2023 by approval for its use together with docetaxel and ADT in metastatic disease, it added. Shweta Rai, Managing Director - India and Country Division Head (South Asia), Bayer's Pharmaceutical Division, said: "India's growing involvement in global clinical trials plays an important role in developing therapies that reflect real-world patient diversity and treatment requirements. The expanded indication of Nubeqa strengthens our efforts in prostate cancer care by providing an additional option for men at advanced stages, particularly those who are ineligible for chemotherapy."

The expanded approval is supported by data from the global Phase III clinical study called ARANOTE which evaluated darolutam-

ide plus ADT in men with metastatic hormone-sensitive prostate cancer.

**INDIA'S KEY ROLE**

India played an important role in the trial, with 93 patients enrolled, representing 14 per cent of the global study population, the note said, adding that AIIMS Delhi was a key trial site, along with additional centres across the country.

Nubeqa (darolutamide), developed jointly by Bayer and Orion Corporation, is a next-generation androgen receptor inhibitor designed with a unique structure that results in minimal blood-brain barrier penetration, reducing the likelihood of fatigue or cognitive concerns seen with some earlier products, the note said.

It also has low potential for drug interactions, making it suitable for older patients or those managing multiple therapies, the company explained.

# Zendesk opens innovation hub

**Our Bureau**  
Pune

Zendesk has inaugurated an Innovation Hub for Research and Development in Pune, expanding its footprint in In-

dia and strengthening its global product development capabilities. The hub has been set up to scale new sources of talent and deepen collaboration across global teams.

**Natural Capsules Limited**  
CIN: L8510KA1993PLC014742  
Trident Towers, 4th Floor (Level 3), No. 23, 100 Feet Road, Jaynagar II Block, Bangalore, Karnataka-560011

**NOTICE OF POSTAL BALLOT & E-VOTING INFORMATION**

NNnotice is hereby given that pursuant to the provisions of Section 108, 110 & other applicable provisions of the Companies Act, 2013 ("Act") read with the Rule 20 & 22 of the Companies (Management & Administration) Rules, 2014 ("the rules"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), Secretarial Standard-2 on General Meeting issued by the Institute of Company Secretaries of India ("ICSI") and in accordance with General Circular Nos 20/2023, 09/2023 and 09/2024 and 5/2025 dated 5th May 2020, 25th September 2023, 19th September 2024 and 22nd September 2025 and respectively and other circulars issued by the Ministry of Corporate Affairs (collectively "MCA Circulars"), and any other applicable laws, rules and regulations, if any, approval of the members of the Natural Capsules Limited ("the Company") is sought through Postal Ballot only by way of electronic means ("remote e-voting"), in relation to the following resolution to be passed as Special resolution as set out in the Postal Ballot Notice ("Notice") dated 13th February, 2026.

- Enhancement in Limits of Investments, Loans, Guarantees, Securities Under Section 186 of the Companies Act, 2013

The detailed explanatory statement under Section 102 of the Act setting out the material facts concerning the resolution, forms part of the Notice.

The notice along with the explanatory statement is available on the Company's website [www.naturalcapsules.com](http://www.naturalcapsules.com), website of stock exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and NSDL (agency for providing the Remote e-Voting facility) at [www.evoting.nsdl.com](http://www.evoting.nsdl.com).

Members are informed that:

- The Company has completed the electronic dispatch of Postal Ballot Notice to the Members on 24th February, 2026.
- The cut-off date for the purpose of ascertaining the eligibility of members to avail remote e-voting is 20th February, 2026. The members whose name is recorded in the Register of Members of the company or in the register of beneficial owners maintained by the depositories as on the cut-off date shall only be entitled to avail the remote e-voting facility. A person who is not a member as on cut-off date should treat this notice for information purpose only. The voting right of the members shall be in proportion of the paid-up equity share capital of the Company as on the cut-off date that is Friday 20th February 2026.
- Members holding shares in physical form who have not registered their email IDs with the Company/RTA of the Company are requested to update their email IDs by writing to [investor@cameoindia.com](mailto:investor@cameoindia.com) along with a copy of the duly filled in & signed form ISR-1 together with the Self attested KYC supporting documents.
- In compliance with the requirements of the MCA Circular, hard copy of the Notice, Postal Ballot form and pre-paid business reply envelope have not been sent to the members for Postal Ballot. Members are required to communicate their assent of dissent only through the remote e-voting system. The company has engaged the services of NSDL for providing the Remote e-Voting facility.
- The detailed procedure/instructions on the process of remote e-voting including the manner in which the members who have not yet registered their email addresses can register their email address and/or can cast their vote is specified in the Notice.
- The remote e-voting period will commence from 09:00 AM (IST) on Thursday, February 26, 2026 and ends at 05:00 PM (IST) on Friday, March 27, 2026. The remote e-voting module shall be disabled thereafter. Once the resolution is cast by a member, no change will be allowed subsequently and no voting shall be allowed beyond the last date.
- In the event of not receiving the postal ballot notice, the member can access and download notice which is available on the Company's website [www.naturalcapsules.com](http://www.naturalcapsules.com), website of stock exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and NSDL (agency for providing the Remote e-Voting facility) at [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
- Mr. Deepak Sadhu (M.No. 39541, COP. 14992), practicing company secretary has been appointed as Scrutinizer for conducting postal ballot through remote e-voting process in a fair and transparent manner.
- The result of the Postal Ballot will be announced on or before 31st March 2026. The result along with the scrutiner report will be displayed at the registered office of the company and also will be hosted at the company's website [www.naturalcapsules.com](http://www.naturalcapsules.com). The result will also be intimated simultaneously to the Stock Exchanges where the Company's shares are listed and on the NSDL.
- In case of any queries and or query, in respect of e-voting by electronic means, Members
  - may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on: 022-48867000 or;
  - send a request to Mr. Falguni Chakraborty at [evoting@nsdl.com](mailto:evoting@nsdl.com) or;
  - can contact to Mr. Vignesh Balaji (Assistant Manager - Shares) of Cameo Corporate Services Limited, our Registrar and Share Transfer Agents for any grievances related to E-voting by writing to them on [vigneshbalaji@cameoindia.com](mailto:vigneshbalaji@cameoindia.com) or calling them on 044-28461073/40020728 between 11.00 A.M. to 7.00 P.M.

The above information is being issued for the benefit of all members of the Company and is in compliance with the Act and MCA Circulars.

Place: Bangalore  
Date: 24th February, 2026

For Natural Capsules Limited  
Sd/- Sunil L. Mundra  
Managing Director

